Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.

Tenny MudiantoKatie M CampbellJason WebbPaul ZolkindZachary L SkidmoreRachel RileyErica K BarnellIbrahim OzgencTusar GiriGavin P DunnDouglas R AdkinsMalachi GriffithAnn Marie EgloffMalachi GriffithRavindra Uppaluri

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

These studies identify a Yap1-dependent resistance to trametinib therapy in HNSCCs. Combined Yap1 and MEK targeting may represent a strategy to enhance HNSCC response.

Keyphrases

squamous cell
high grade
stem cells
drug delivery
bone marrow
signaling pathway